Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 5/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.33 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.31 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19981007 | 1.00 | P2RY6 (0.34) | P2RY6P2RY14NT5EMAPTROCK2 | |
| SCHEMBL14946367 | 1.00 | P2RY6 (0.34) | P2RY6P2RY14NT5EMAPTROCK2 | |
| SCHEMBL10459464 | 1.00 | P2RY6 (0.34) | P2RY6P2RY14NT5EMAPTROCK2 | |
| SCHEMBL20215740 | 1.00 | P2RY6 (0.34) | P2RY6P2RY14NT5EMAPTROCK2 | |
| SCHEMBL20459987 | 1.00 | P2RY6 (0.34) | P2RY6P2RY14NT5EMAPTROCK2 | |
| SCHEMBL14946314 | 0.92 | MAPT (0.32) | P2RY6P2RY14NT5EMAPTROCK2 | |
| SCHEMBL16229229 | 0.89 | MAPT (0.31) | MAPTABL1RIN1 | |
| SCHEMBL13151571 | 0.89 | P2RY6 (0.47) | P2RY6P2RY14NT5EP2RY2P2RY4 | |
| SCHEMBL6365808 | 0.89 | P2RY6 (0.47) | P2RY6P2RY14NT5EP2RY2P2RY4 | |
| SCHEMBL13672352 | 0.89 | P2RY6 (0.47) | P2RY6P2RY14NT5EP2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230383287-A1 | ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOF | HELIX NANOTECHNOLOGIES INC | 2023-11-30 | — | — | US | disclosed |
| US-20230383287-A1 | ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOF | HELIX NANOTECHNOLOGIES INC | 2023-11-30 | — | — | US | disclosed |
| US-11542505-B1 | Substituted RIG-I agonists: compositions and methods thereof | MERCK SHARP & DOHME LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-10597421-B2 | Protected monomer and method of final deprotection for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| EP-3424510-A1 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF 2'-CYANO-2'-DEOXY-N4-PALMITOYL-1-BETA-D-ARABINOFURANOSYLCYTOSINE | Cyclacel Limited (GB) | 2019-01-09 | — | — | EP | disclosed |
| EP-2331558-B1 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES INC (US) | 2018-09-12 | — | — | EP | disclosed |
| EP-2291193-B1 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF 2'-CYANO-2'-DEOXY-N4-PALMITOYL-1-BETA-D-ARABINOFURANOSYLCYTOSINE | CYCLACEL LTD (GB) | 2018-08-08 | — | — | EP | disclosed |
| US-20180186826-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. | 2018-07-05 | — | — | US | disclosed |
| US-9896472-B2 | Protected monomer and method of final deprotection for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-9273086-B2 | Protected monomer and method of final deprotection for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20140206640-A1 | 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140161770-A1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF USEFUL FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140154211-A1 | 2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2014-06-05 | — | — | US | disclosed |
| US-20140128339-A1 | 2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. | 2014-05-08 | — | — | US | disclosed |
| US-20120289691-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120184724-A1 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2331558-A2 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | Agilent Technologies, Inc. (US) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010034024-A2 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20100076183-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. | 2010-03-25 | — | — | US | disclosed |
| EP-0661291-A1 | Solid phase synthesis of oligoribonucleotide | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140161770-A1 | 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF USEFUL FOR THE TREATMENT OF VIRAL DISEASES | HCCS, NSUN2, PNP | P2RY6 940/4885P2RY14 943/4885NT5E 39/4885 |
| US-20120289691-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | NSUN2, SNRPB2, RNGTT | P2RY6 2782/4885P2RY14 1960/4885NT5E 1105/4885 |
| US-20140128339-A1 | 2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | NSUN2, NT5C3B, MTAP | P2RY6 537/4885P2RY14 765/4885NT5E 63/4885 |
| US-20230383287-A1 | ACETYLATED RIBONUCLEIC ACIDS AND USES THEREOF | NSUN2, NSUN3, ADAR | P2RY6 3557/4885P2RY14 3491/4885NT5E 301/4885 |
| US-20140154211-A1 | 2'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | SLC29A2, SLC29A1, SLC28A2 | P2RY6 396/4885P2RY14 472/4885NT5E 29/4885 |
| US-20140206640-A1 | 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | ADAR, SLC29A1, SLC28A1 | P2RY6 255/4885P2RY14 285/4885NT5E 56/4885 |
| US-20180186826-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | NSUN2, RNGTT, RNMT | P2RY6 4301/4885P2RY14 3860/4885NT5E 660/4885 |
| US-20100076183-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | RNGTT, RNMT, NSUN2 | P2RY6 2962/4885P2RY14 2787/4885NT5E 324/4885 |
| US-11542505-B1 | Substituted RIG-I agonists: compositions and methods thereof | MAVS, TLR3, DDX18 | P2RY6 1226/4885P2RY14 1655/4885NT5E 562/4885 |
| US-10597421-B2 | Protected monomer and method of final deprotection for RNA synthesis | NSUN2, RNGTT, RNMT | P2RY6 4301/4885P2RY14 3860/4885NT5E 660/4885 |
| US-20120184724-A1 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS | RNMT, RNGTT, NSUN2 | P2RY6 3378/4885P2RY14 2202/4885NT5E 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.